



## COMPANY OVERVIEW

Cardax is a consumer health company focused on marketing ZanthoSyn<sup>®</sup>, a physician recommended astaxanthin dietary supplement for inflammatory health.\* Cardax previously focused on development of pharmaceuticals for diseases driven by inflammation. Cardax may seek to monetize CDX-101, the Company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company's pre-clinical pharmaceutical candidate for macular degeneration.

## RECENT NEWS

### Cardax Refocuses on ZanthoSyn<sup>®</sup> Consumer Health Business

Aug 31 2021, 6:18 PM EDT

### Cardax Voluntarily Suspends SEC Reporting Obligations

Aug 11 2021, 5:00 PM EDT

## STOCK OVERVIEW

Symbol	CDXI
Exchange	OTCQB
Market Cap	
Last Price	\$
52-Week Range	\$ - \$

## INVESTOR RELATIONS

Cardax, Inc.  
T: (808) 457-1400  
[investors@cardaxpharma.com](mailto:investors@cardaxpharma.com)

## MANAGEMENT TEAM

**David G. Watumull**  
Chairman and CEO

**David M. Watumull**  
COO and CFO

## CARDAX, INC.

2800 Woodlawn Drive  
Suite 129  
Honolulu, HI 96822

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.